Clinical Trials Browser

Recruiting × Pathologic Complete Response × Clear all

NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07586813 2026-05-14

N01-A-PICIT-GI

Phase 2 Recruiting

Classical hematologyGastrointestinal

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

Phase 2 Recruiting

BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

Pathologic Complete Response, Neoplasm, Residual

NCT04055220 2026-02-17

REGOSTA

Phase NA Recruiting

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2 Recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07353840 2026-01-20

T-START-CR

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT06364371 2025-12-18

Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

Pathologic Complete Response

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

Phase NA Recruiting

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT07166185 2025-09-10

NEOTRAPSCAL

Pathologic Complete Response, Breast Neoplasms

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Phase 2 Recruiting

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06111807 2025-03-30

MRD-LUNG

Pathologic Complete Response, Hypersensitivity, Lung Neoplasms, Neoplasm, Residual

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

Phase NA Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

Phase NA Recruiting

Pathologic Complete Response, Breast Neoplasms, Motor Activity

NCT04314219 2025-03-13

PTCy-PMAT

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05350722 2024-12-30

ABLATIVE-2

Phase NA Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05000697 2024-11-27

CCHOWW

Phase NA Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT06182657 2024-02-08

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT03125343 2023-11-07

WoW

Phase NA Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT04743102 2023-02-21

BIOPSY

Phase NA Recruiting

Gastrointestinal

Pathologic Complete Response, Neoplasm Metastasis, Rectal Neoplasms

NCT04293796 2022-06-15

VAB

Phase NA Recruiting

Pathologic Complete Response

NCT03426397 2020-07-29

"Wait-and-see" Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms